Atezolizumab Biosimilar - Research Grade

Product Specifications

Background

Atezolizumab biosimilar is an Fc-engineered, humanized, monoclonal antibody that binds to PD-L1 and blocks interactions with the PD-1 and B7.1 receptors. Atezolizumab biosimilar is a non-glycosylated IgG1 kappa immunoglobulin that has a calculated molecular mass of 145 kDa.

Specifications

Detects human PDL-1. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Atezolizumab.

Product Name Alternative

Programmed cell death 1 ligand 1, Cd274, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1, PDL-1

UniProt

Q9NZQ7

Host

Humanized

Species Reactivity

Human

Target

PD-L1

Purification Method

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Concentration

1.0 - 5.0 mg/mL

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>95% by SDS-PAGE and HPLC

Buffer

ICH3001-100mL ICH3002-100mL ICH3003-100mL

Shipping Conditions

Blue ice

Storage Conditions

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.